Ancilia Biosciences Awarded NSF Grant to Advance Platform Designed to Address Overlooked Obstacle to Success for Microbiome Therapeutics
Retrieved on:
Tuesday, August 3, 2021
We founded Ancilia to overcome what our researchers believe is a significant obstacle to this successthe failure to address the presence of phages that infect commensal microbiome bacteria.
Key Points:
- We founded Ancilia to overcome what our researchers believe is a significant obstacle to this successthe failure to address the presence of phages that infect commensal microbiome bacteria.
- There is evidence that phages are associated with disease and that they may also compromise the efficacy of LBPs.
- We are delighted that the NSF sees potential in our technology and is supporting further development of our platform."
- Ancilia Biosciences ( www.anciliabio.com) is developing virus-resistant live bacterial biotherapeutics (LBPs) to alter the gut microbiome and treat disease.